N-ureidoalkyl-piperidines modulating chemokine receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases such as asthma and autoimmune pathologies like rheumatoid arthritis lack effective agents that modulate chemokine receptors, which are crucial in mediating inflammatory responses and immune regulation.
Innovation Solution
Development of novel N-ureidoalkyl-piperidines that act as agonists or antagonists of CCR-3 and CCR-1 chemokine receptors, formulated into pharmaceutical compositions for therapeutic use in treating inflammatory and allergic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for inflammatory diseases are used, then existing therapies provide some level of treatment, but effective modulation of chemokine receptors is lacking
Solution Approach 1:
The patent develops a series of N-ureidoalkyl-piperidine compounds that can function as agonists or antagonists at multiple chemokine receptors (CCR-1 and CCR-3), enabling a single compound class to address diverse inflammatory conditions including asthma, allergic disorders, and autoimmune pathologies through versatile receptor modulation
Solution Approach 2:
The invention employs systematic modification of molecular parameters (substituents at R1, R2, R4a, R4b, R5 positions) to optimize compound properties, creating a library of variants with different affinities and selectivities for chemokine receptors, thereby improving reliability of modulation across different disease models
2Reliability
If novel N-ureidoalkyl-piperidines are developed, then effective chemokine receptor modulation is achieved, but compound complexity increases
Solution Approach 1:
The patent divides the molecular structure into distinct functional segments: a piperidine core scaffold, ureidoalkyl side chains with specific substituents (R1-R5), and variable groups at defined positions. This segmentation allows independent optimization of each segment's contribution to receptor binding and activity while maintaining overall manageable complexity
Solution Approach 2:
The invention applies local quality by introducing specific functional groups and substituents at particular positions (R1, R2, R4a, R4b, R5) of the piperidine scaffold, where each position is optimized for specific interactions with chemokine receptors, thereby achieving reliable modulation without requiring complete structural complexity
3Adaptability or versatility
If multiple chemokine receptors are targeted, then therapeutic coverage expands, but selectivity and specificity become more difficult to achieve
Solution Approach 1:
The patent creates dynamic selectivity through variable substituents that can be adjusted to favor binding at specific chemokine receptors (CCR-1 or CCR-3) based on the disease model, allowing the same compound class to adapt its binding preferences through molecular parameter changes rather than requiring entirely different compounds for different targets
Data Source
AI summary
The present application describes modulators of chemokine receptor activity of formula (I):or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, including methods of preparing and intermediates thereof.